DEADLINE ALERT for ACB, PRU, FCAU, CORV: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

This Post Was Syndicated Under License Via QuoteMedia

BENSALEM, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) — Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. 

Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected].

Aurora Cannabis Inc. (NYSE: ACB)
Class Period:   September 11, 2019 – November 14, 2019
Lead Plaintiff Deadline: January 21, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Aurora’s revenue would decline in its first quarter of fiscal 2020 ended September 30, 2019; (2) that the Company would halt construction on its Aurora Nordic 2 and Aurora Sun facilities; and (3) that as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Prudential Financial, Inc. (NYSE: PRU)
Class Period: February 15, 2019 – August 2, 2019
Lead Plaintiff Deadline: January 27, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company’s reserve assumptions failed to account for adversely developing mortality experience in its Individual Life business segment; (2) that the Company was not over-reserved, but instead, its reported reserves, particularly for the Individual Life business segment, were insufficient to satisfy its future policy benefits liabilities; and (3) that the Company had materially understated its liabilities and overstated net income as a result of flawed assumptions in calculating mortality experience.

Fiat Chrysler Automobiles N.V. (NYSE: FCAU)
Class Period:  February 26, 2016 – November 20, 2019
Lead Plaintiff Deadline: January 31, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Fiat employed a bribery scheme to obtain favorable terms in its collective bargaining agreement with International Union, United Automobile, Aerospace and Agricultural Implement Workers of America; (2) that high-ranking Fiat officials were aware of and authorized the scheme; and (3) that due to the foregoing, defendants’ statements about Fiat’s receivables, business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Correvio Pharma Corporation (NASDAQ: CORV)
Class Period:   October 23, 2018 – December 5, 2019
Lead Plaintiff Deadline: February 10, 2020

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the data supporting the Resubmitted New Drug Application (“NDA”) for Brinavess did not minimize the significant health and safety issues observed in connection with the drug’s original NDA; (2) that the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) that, as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com